The stock of XBiotech Inc (NASDAQ:XBIT) is a huge mover today! About 47,395 shares traded hands. XBiotech Inc (NASDAQ:XBIT) has risen 58.88% since March 11, 2016 and is uptrending. It has outperformed by 53.42% the S&P500.
The move comes after 7 months negative chart setup for the $437.34M company. It was reported on Oct, 14 by Barchart.com. We have $11.84 PT which if reached, will make NASDAQ:XBIT worth $52.48 million less.
Analysts await XBiotech Inc (NASDAQ:XBIT) to report earnings on November, 11. They expect $-0.38 earnings per share, down 15.15% or $0.05 from last year’s $-0.33 per share. After $-0.42 actual earnings per share reported by XBiotech Inc for the previous quarter, Wall Street now forecasts -9.52% EPS growth.
According to Zacks Investment Research, “XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.”
More notable recent XBiotech Inc (NASDAQ:XBIT) news were published by: Fool.com which released: “Why XBiotech Inc. Fell 33% Today” on July 05, 2016, also Marketwatch.com with their article: “XBiotech Inc. NASDAQ: XBIT” published on April 15, 2015, Fool.com published: “Why XBiotech Inc. Made a U-Turn Today” on December 08, 2015. More interesting news about XBiotech Inc (NASDAQ:XBIT) were released by: Quotes.Wsj.com and their article: “XBiotech Inc. XBIT (US: Nasdaq)” published on April 15, 2015 as well as Globenewswire.com‘s news article titled: “XBiotech Signs Agreement With Megapharm To Market Xilonixâ„¢ In Israel” with publication date: June 28, 2016.
XBIT Company Profile
XBiotech Inc., incorporated on October 23, 2005, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Firm focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Firm has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody, Xilonix, is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.